C2603343||study
C0013161||solid lipid-polyethyleneimine hybrid nanocarrier
C0006826||cancer
C4042855||RNAi therapy
C0013161||Solid lipid-polymer hybrid nanocarrier
C0013161||lipid-polymer hybrid nanocarrier
C1099354||siRNA
C0040669||transfection
C1136031||RNAi
C1527144||chemosensitizing effect
C2603343||study
C1515655||in vivo
C0013161||LPNs
C0600139||prostate cancer
C0027651||tumor
C0013161||LPNs
C0013161||lipid-polymer hybrid nanocarrier
C0013058||formulation
C0040669||transfection
C2603343||study
C0025929||Mice
C0027651||tumors
C1513528||PC-3Mcells
C0013161||LPNs
C2933062||IR780
C3489916||AF647
C1099354||siRNA
C4288612||Near infrared imaging
C0013161||LPNs
C1515655||in vivo
C0027651||tumor
C0178784||organ
C0013161||lipid-polymer hybrid nanocarrier
C4055506||accumulation
C0023884||liver
C0475358||metastatic tissue
C0015376||extravasation
C2603343||study
C1099354||siRNA
C0475358||tumor tissue
C0005898||extravascular area
C0013161||lipid-polymer hybrid nanocarrier
C0027651||tumors
C0246415||docetaxel
C0013161||lipid-polymer hybrid nanocarrier
C0246415||docetaxel
C0087111||treatment
C0027651||tumor
C0013161||lipid-polymer hybrid nanocarrier
C0013161||lipid-polymer hybrid nanocarrier
C0013161||carrier system
C4042855||RNAi therapy
C4282132||solid malignancies
C3665472||chemotherapy